Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$1.9BCash on Hand
CF+ Cash Runway
1.6%Short Interest
$65.01Analyst Target (11)
Follow GMAB by emailGet an email when GMAB reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about GMAB, unsubscribe in one click. Privacy
📣 What GMAB Says Is Next
during 2026 · “The financial guidance assumes that no significant new agreements are entered into during 2026 Genmab A/S Carl Jacobsens Vej 30 2500 Valby, Denmark Tel: +45 7020 2728 www.genmab.com Company Announcement no. 45 Page 6/45 CVR no. 2102 3884 Interim Report for the Nine Months of 2026 that could materially affect the results.”
Company press release, Nov 5, 2026 · SEC filing
fourth quarter · Epcoritamab: “As anticipated, we are now in our data-rich fourth quarter, where we have delivered pivotal readouts across our three late-stage assets, epcoritamab, Rina-S ® (rinatabart sesutecan) and petosemtamab, supporting multiple regulatory submissions and potential launches in 2027,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.”
Company press release, Nov 5, 2026 · SEC filing
during 2026 · “The financial guidance assumes that no significant new agreements are entered into during 2026 that could materially affect the results.”
Company press release, Aug 6, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Filing is a cover page for November 2026 with an exhibit index listing only Exhibit 3.1, Articles of Association, and no substantive text. Form 6-K · SEC filing
Nov 12, 2026 ·
Leadership Executive Vice President and Chief Commercial Officer Bradley Bailey sold 1,071 Genmab shares at an average DKK 3,602.98 on November 11, 2026, on NASDAQ Copenhagen. Form 6-K · SEC filing · Press release
Nov 12, 2026 ·
Leadership Two Board members, Martin Schultz and Mijke Zachariasse, each sold Genmab shares on November 12, 2026: 617 shares and 351 shares, both at DKK 3,540.87 per share. Form 6-K · SEC filing · Press release
Nov 5, 2026 ·
Earnings Nine-month revenue rose 22% to $3,238 million, driven by DARZALEX and Kesimpta royalties and higher EPKINLY net sales. Operating profit fell to $986 million from $1,007 million. Positive Phase 3 topline results were reported for epcoritamab, Rina-S and petosemtamab in October. Form 6-K · SEC filing · Press release
Oct 28, 2026 ·
Clinical trial Phase 3 LiGeR-HN1 trial of petosemtamab plus pembrolizumab met both dual primary endpoints at the first interim analysis in first-line PD-L1+ recurrent/metastatic head and neck cancer. Overall survival HR was 0.50 (p<0.0001) and objective response rate odds ratio was 3.17 (p<0.0001). Form 6-K · SEC filing · Press release
Oct 23, 2026 ·
Clinical trial Phase 3 RAINFOL-02 trial of rinatabart sesutecan (Rina-S) met its primary PFS endpoint in platinum-resistant ovarian cancer, with HR 0.29 in the ITT population (71% risk reduction, p<0.0001) and HR 0.33 in the PAS population. Key secondary endpoint OS also met, HR 0.43 ITT (p<0.0001). No new safety signals. Form 6-K · SEC filing · Press release
Oct 13, 2026 ·
Earnings Worldwide net trade sales of DARZALEX, including the subcutaneous product, were USD 4,239 million in Q3 2026, with USD 2,528 million in the U.S. and USD 1,711 million in the rest of the world. Genmab receives royalties on these sales. Form 6-K · SEC filing · Press release
Oct 7, 2026 ·
Shareholder vote At an Extraordinary General Meeting, shareholders approved the 2026 Board remuneration proposal, under which 5,300 restricted stock units were granted to Board members at a fair value of DKK 2,487.00 per unit, vesting after three years. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Mar 2027 · Phase 2 · Active Trial · A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic… Registry primary completion date, not a results date
Jun 2027 · Phase 3 · Active Trial · A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone… Registry primary completion date, not a results date
Jul 2027 · Phase 3 · Active Trial · Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) Registry primary completion date, not a results date
Aug 2027 · Phase 1 · Active Trial · A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors Registry primary completion date, not a results date
Sep 2027 · Phase 1/2 · Active Trial · Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) Registry primary completion date, not a results date
Sep 2027 · Phase 3 · Recruiting · An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not GMAB's own candidates): Gemcitabine Hydrochloride, Leucovorin, Oxaliplatin, Paclitaxel, Pembrolizumab, Prednisone, Rituximab, Topotecan, Carboplatin, Cetuximab, Bevacizumab, Cyclophosphamide.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
GMAB holds $1.9B in cash and short-term investments and its operations are currently cash-flow neutral or positive.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GMAB and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.